E. Jassem (Gdansk, Poland), R. Wiewrodt (Mainz, Germany)
Influences of ethnic and environmental factors in the mutation patterns in the p53 gene
L. Zambon, M. W. Perroud Jr, H. N. Honma, F. F. Costa, A. S. Barbeiro, J. T. Seabra (Campinas, Brazil)
|  |
Lung cancer in smoking patients inversely alters Fpg and endonuclease III human homologues
I. Horváth, S. Goto, H. Nakamoto, K. Udud, Z. Pápai, Z. Radák (Budapest, Hungary; Funabashi, Japan)
| |
Genetic polymorphism of epoxide hydrolase and GSTM1 in lung cancer susceptibility
K. O. Park, Y. C. Kim, K. S. Kim, K. J. Na, J. T. Park, E. J. Kim (Kwangju, South Korea)
| |
The expression of Ki-67 in preneoplastic and early neoplastic bronchial lesions
A. P. Meert, J. M. Verdebout, F. Feoli, B. Martin, A. Verhest, V. Ninane, J. P. Sculier (Brussels, Belgium)
| |
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients
A. Kaya, B. E. Gulbay, G. Celik, O. U. Gurkan, H. Savas, I. Savas (Ankara, Turkey)
| |
Antirecoverin autoantibodies in sera of patients with non-small cell lung cancer in the absence of cancer-associated retinopathy
O. N. Shifrina, A. V. Bazhin, M. S. Savchenko, A. G. Chuchalin, P. P. Phlilippov (Moscow, Russia)
| |
Serum levels of STR-3 and TIMP-2 in lung cancer
K. D. Hatzakis, M. E. Froudarakis, A. Karameris, N. Tzanakis, N. M. Siafakas, D. Bouros (Heraklion, Athens, Greece)
| |
Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients
J. Jassem, E. Jassem, A. Badzio, G. Kobierska, A. Szymanowska, M. Skrzypski, J. Skokowski, M. Zylicz (Gdansk, Poland)
| |
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker
C. Mascaux, B. Martin, A. P. Meert, J. M. Verdebout, M. Paesmans, V. Ninane, J. P. Sculier (Brussels, Belgium)
| |
HER-2/neu oncoprotein expression in nonsmall cell lung cancer
K. Junker, K. Langner, M. Thomas, F. Klinke, K. M. Mueller (Bochum, Münster, Ostercappeln, Germany)
| |
Studies on clinical significance and relationship with PI and gene protein expression of p16, Rb and Cyclin-D1 in lung cancer
H. Gao, J. Da, D. Xu, K. Zhang, B. Zhang, J. Liu, L. Xie (Hangzhou, China)
| |
Pro-GRP as a diagnostic tool in SCLC in comparison to NSE
M. W. R. Pletz, O. Burkhardt, N. Schoenfeld, H. Lode (Berlin, Germany)
| |
Expression of LFA-1 and L-selectin on PMN and level of soluble sE-selectin and sL-selectin in patients with small cell lung cancer (SCLC)
A. Izycka, E. Jablonska, T. Izycki, E. Chyczewska (Bialystok, Poland)
| |
Dopaminergic markers in human small cell lung cancer
A. Ricci, E. Bronzetti, G. Schmid, S. Mariotta, F. Mannino, F. Mignini, F. Amenta (Rome, Camerino, Italy)
| |
Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer
R. Ishibashi, Y. Nakanishi, M. Izumi, N. Inoshima, K. Inoue, H. Wataya, T. Minami, Y. Horiuchi, N. Hara (Fukuoka, Japan)
| |
Alteration of neutrophil invasion toward malignant mesothelioma by Interleukin-10
G. Galffy, A. Lantos, L. Tamasi, V. B. Antony, P. Magyar (Budapest, Hungary; Indianapolis, United States Of America)
| |
Tumour necrosis correlates with angiogenesis and is a prognostic factor in malignant mesothelioma
J. G. Edwards, D. Swinson, L. Jones, D. A. Waller, K. J. O'Byrne (Leicester, United Kingdom)
| |
Gene expression mapping to diagnose malignant mesothelioma
R. Wiewrodt, S. Singhal, L. Malden, K. Matzie, J. Kucharczuk, J. Friedberg, L. R. Kaiser, S. M. Albelda (Philadelphia, United States Of America; Mainz, Germany)
| |
Pancreatic polypeptide is increased in patients with advanced malignant disease including lung cancer
A. Hjalmarsen, R. M. Bremnes, U. Aasebø, R. Jorde (Tromso, Norway)
| |
The biological features of dendritic cells (DC) induced in malignant pericardial effusion
J. A. Huang, Y. D. Wang, Y. B. Zhu, J. Y. Ma, G. J. Wang, X. G. Zhang (Suzhou, China)
| |